Similar articles for PMID: 19901015

Year	Number of Results
1992	1
1996	1
1999	2
2000	1
2002	2
2003	1
2005	1
2006	5
2007	5
2008	3
2009	5
2010	11
2011	2
2012	8
2013	5
2014	5
2015	8
2016	8
2017	5
2018	8
2019	6
2024	0

1

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.

Glimelius B, Lahn M, Gawande S, Cleverly A, Darstein C, Musib L, Liu Y, Spindler KL, Frödin JE, Berglund A, Byström P, Qvortrup C, Jakobsen A, Pfeiffer P. Glimelius B, et al. Ann Oncol. 2010 May;21(5):1020-6. doi: 10.1093/annonc/mdp521. Epub 2009 Nov 9. Ann Oncol. 2010. PMID: 19901015 Free article. Clinical Trial.

2

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.

Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V. Wolff RA, et al. Cancer. 2012 Sep 1;118(17):4132-8. doi: 10.1002/cncr.26692. Epub 2011 Dec 27. Cancer. 2012. PMID: 22213153 Free article. Clinical Trial.

3

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Oh Y, et al. J Clin Oncol. 2008 Mar 1;26(7):1135-41. doi: 10.1200/JCO.2007.14.3685. J Clin Oncol. 2008. PMID: 18309949 Clinical Trial.

4

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M. Morschhauser F, et al. Ann Oncol. 2008 Feb;19(2):247-53. doi: 10.1093/annonc/mdm463. Epub 2007 Sep 28. Ann Oncol. 2008. PMID: 17906297 Free article. Clinical Trial.

5

Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.

He WZ, Rong YM, Jiang C, Liao FX, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP. He WZ, et al. Chin J Cancer. 2016 Jun 29;35(1):58. doi: 10.1186/s40880-016-0120-4. Chin J Cancer. 2016. PMID: 27357402 Free PMC article. Clinical Trial.

6

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.

Glimelius B, Spindler KL, Frödin JE, Berglund A, Byström P, Qvortrup C, Jakobsen A, Pfeiffer P. Glimelius B, et al. Ann Oncol. 2010 May;21(5):1127-8. doi: 10.1093/annonc/mdp526. Epub 2009 Nov 13. Ann Oncol. 2010. PMID: 19914961 Free article. Clinical Trial. No abstract available.

7

Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.

Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N. Casey EM, et al. J Thorac Oncol. 2010 Nov;5(11):1815-20. doi: 10.1097/JTO.0b013e3181ee820c. J Thorac Oncol. 2010. PMID: 20881647 Free article. Clinical Trial.

8

A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.

Tanai C, Yamamoto N, Ohe Y, Takahashi T, Kunitoh H, Murakami H, Yamamoto N, Nakamura Y, Nokihara H, Shukuya T, Baldwin JR, Koshiji M, Tamura T. Tanai C, et al. J Thorac Oncol. 2010 Jul;5(7):1068-74. doi: 10.1097/JTO.0b013e3181da3899. J Thorac Oncol. 2010. PMID: 20453691 Free article. Clinical Trial.

9

Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.

Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, Francini E. Petrioli R, et al. Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21. Clin Colorectal Cancer. 2018. PMID: 29548772

10

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

77 results

Results by year